Revvity Reports $711.1 Million Revenue in Q1 2026, Driven by Diagnostics and Life Sciences Growth

Revvity, Inc. reported a total revenue of $711.1 million for the first quarter of fiscal year 2026, marking a 7% increase from $664.8 million in the same period last year. The growth was driven by an 8% increase in the Diagnostics segment, which generated $349.3 million, and a 6% increase in the Life Sciences segment, which brought in $361.8 million. The company’s operating income from continuing operations was $75.9 million, slightly up from $72.2 million a year earlier, while net income decreased to $40.7 million from $42.2 million, reflecting a decline in comprehensive income due to foreign currency translation adjustments.

In terms of operational metrics, Revvity's gross margin decreased to 54.5% from 56.5% year-over-year, primarily due to a shift in product mix, increased tariffs, and the impact of an extra fiscal week. Selling, general, and administrative expenses rose to $253.9 million, up 2% from the previous year, while research and development expenses increased by 8% to $57.9 million, reflecting ongoing investments in new product development. The company also reported a decrease in its basic earnings per share to $0.36 from $0.35, with diluted earnings per share remaining consistent at $0.37.

Strategically, Revvity completed the acquisition of Advanced Chemistry Development Inc. for $72 million, enhancing its capabilities in scientific software solutions. This acquisition is expected to bolster the company’s Life Sciences segment. Additionally, Revvity has initiated a stock repurchase program, authorizing up to $1 billion, with $79 million spent on repurchasing shares in the first quarter. The company also declared a quarterly dividend of $0.07 per share, consistent with previous quarters.

Geographically, Revvity's revenue from the Americas was $316 million, while Europe and Asia contributed $223 million and $172 million, respectively. The company reported a total of 111.6 million shares outstanding as of April 5, 2026, down from 112.3 million at the end of the previous fiscal year. The company’s cash and cash equivalents stood at $860.3 million, with $1.5 billion available under its revolving credit facility, indicating a strong liquidity position.

Looking ahead, Revvity anticipates continued growth driven by its strategic investments and acquisitions, although it acknowledges potential challenges from market conditions and regulatory changes. The company expects to maintain its focus on innovation and operational efficiency to navigate these challenges while aiming for a stable effective tax rate of approximately 20% for the fiscal year.